Date published: 2026-4-5

1-800-457-3801

SCBT Portrait Logo
Seach Input

Paraxanthine-d3 (CAS 65566-70-3)

0.0(0)
Write a reviewAsk a question

Alternate Names:
3,7-Dihydro-1-methyl-7-(methyl-d3)-1H-purine-2,6-dione
CAS Number:
65566-70-3
Molecular Weight:
183.18
Molecular Formula:
C7H5D3N4O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Paraxanthine-d3, a labeled isotope of paraxanthine, serves as a dependable tool in scientific investigations concerning caffeine′s metabolism and pharmacokinetics. Paraxanthine-d3 exhibits antagonistic properties towards adenosine receptors within the brain. Adenosine, a neurotransmitter known for inducing sleep and reducing arousal, is counteracted by Paraxanthine-d3, which effectively blocks these receptors and stimulates wakefulness and attentiveness. This compound generates a range of biochemical and physiological effects. It enhances the presence of catecholamines like dopamine and norepinephrine in the brain, while also boosting the release of acetylcholine, a neurotransmitter that supports cognitive function. Furthermore, Paraxanthine-d3 elevates the metabolic rate and facilitates lipolysis, the process responsible for fat breakdown.


Paraxanthine-d3 (CAS 65566-70-3) References

  1. Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis.  |  Li, H., et al. 2017. Drug Metab Dispos. 45: 1317-1325. PMID: 28986475
  2. Monitoring caffeine intake in children with a questionnaire and urine collection: a cross-sectional study in a convenience sample in Switzerland.  |  Rios-Leyvraz, M., et al. 2020. Eur J Nutr. 59: 3537-3543. PMID: 32016643
  3. Methamphetamine administration increases hepatic CYP1A2 but not CYP3A activity in female guinea pigs.  |  Soo, JY., et al. 2020. PLoS One. 15: e0233010. PMID: 32396581
  4. A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects.  |  Thai, C., et al. 2021. Clin Pharmacol Drug Dev. 10: 1279-1289. PMID: 33951339
  5. Intrauterine growth restriction alters the activity of drug metabolising enzymes in the maternal-placental-fetal unit.  |  McBride, GM., et al. 2021. Life Sci. 285: 120016. PMID: 34614415
  6. Simultaneous determination of caffeine and its metabolites in rat plasma by UHPLC-MS/MS.  |  Kertys, M., et al. 2021. J Sep Sci. 44: 4274-4283. PMID: 34626085
  7. Maternal-placental-fetal drug metabolism is altered by late gestation undernutrition in the pregnant ewe.  |  Meakin, AS., et al. 2022. Life Sci. 298: 120521. PMID: 35367241

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Paraxanthine-d3, 1 mg

sc-477805
1 mg
$459.00